GENEVA, July 9 -- ENDOCURA INC. (404, 8, Gyeonggyojang-gilJongno-guSeoul 03181), 주식회사 엔도큐라 (서울특별시종로구경교장길 8, 404호), SAMSUNG MEDICAL FOUNDATION (29, Saemunan-roJongno-guSeoul 03181), (의) 삼성의료재단 (서울특별시종로구새문안로 29) filed a patent application (PCT/KR2024/005715) for "PHARMACEUTICAL COMPOSITION FOR DISRUPTION OF TUMOR BLOOD VESSELS" on Apr 26, 2024. With publication no. WO/2025/143377, the details related to the patent application was published on Jul 03, 2025.
Notably, t...